Research Spotlight: Chronic Migraine Prevention in Diverse Populations – COMPEL Trial
By: Brooklyn A. Bradley, BS; Medically edited by Dr. Deena Kuruvilla, MD
Chronic migraine is more than “just a headache.” It is a complex neurological condition that can significantly impact work, relationships, and overall quality of life. Research also shows that many patients face barriers to diagnosis and treatment depending on their background or access to care.
A recent study called the COMPEL trial recently explored an important question: Do preventive migraine treatments work similarly for people from different racial and ethnic groups? [1]
Our Medical Director, Dr. Deena Kuruvilla, served as a study author in the post-hoc analysis of this phase-4 COMPEL trial and was recently interviewed by NeurologyLive ® to discuss the findings [2].
Here’s what the findings mean for patients.
Why This Research Matters:
Previous studies show differences in:
- Migraine symptoms and severity
- Access to care
- Treatment use
- Quality of life among patients with migraine
However, there has been limited data on whether preventive treatments work equally well across different populations. This study helps address that gap.
What Was Studied?
Researchers analyzed data from a large clinical trial that followed adults with chronic migraine for more than 2 years.
Participants received a preventive treatment called onabotulinumtoxinA every 12 weeks and researchers evaluated:
- Changes in monthly headache days
- Migraine-related disability
- Daily functioning and quality of life
- Safety and side effects
- Treatment response across racial groups
The study included patients who identified as White, Asian, and Black/African American subgroups.
Key Findings for Patients:
Participants in every group experienced significant reductions in monthly headache days over time.
- Many patients cut their headache days in half or more
- Improvements continued throughout treatment
- Results were similar across different populations
Preventive treatment can be effective for diverse patient groups when access to care is available.
Migraine Disability and Quality of Life
The study looked beyond headache frequency and measured how migraine affects everyday life.
Patients reported improvements in:
- Daily functioning
- Work productivity and activities
- Emotional well-being
- Overall quality of life
Some patients also showed improvements in anxiety and depression symptoms during treatment.
Benefits Increased Over Time
Headache days continued to decrease throughout the 108-week study. Some patients – particularly in certain groups – showed slower early improvement but strong long-term benefit. Overall, preventive migraine care appears to work gradually and requires consistency.
Safety
No new safety concerns for onabotulinumtoxinA were identified. The most common side effects included neck pain, temporary eyelid drooping, muscle stiffness, and injection-site discomfort. Side effects were similar across groups.
Findings About Migraine Care
One important finding was that differences in outcomes may be more related to access to care than differences in how treatment works.
Researchers observed:
- Differences in prior use of preventive treatments
- Challenges staying in long-term care for some patients
- Higher loss to follow-up in certain groups
These findings highlight the importance of removing barriers such as transportation, scheduling, insurance, challenges, and access to specialists.
Conclusion
The COMPEL study helped reinforce several important messages. Preventive migraine treatments can help many patients. Long-term care and follow-up improve results, and access to care plays a major role in outcomes.
References:
- Blumenfeld AM, Charleston L, Kuruvilla D, et al. OnabotulinumtoxinA treatment among diverse racial groups: post hoc analysis of the phase 4 chronic migraine onabotulinumtoxinA prolonged efficacy open‐label (compel) trial. Headache. Published online December 15, 2025:head.70007. doi:10.1111/head.70007
- Meglio M, Kuruvilla D. Chronic Migraine Prevention in Diverse Populations: What the COMPEL Trial Reveals. NeurologyLive. https://www.neurologylive.com/view/chronic-migraine-prevention-diverse-populations-what-compel-trial-reveals